T1	PROC 46 73	Estudio sin enmascaramiento
T2	Neg_cue 54 57	sin
T3	Negated 58 73	enmascaramiento
T4	Date 74 87	a largo plazo
T5	PROC 93 127	evaluar la seguridad y la eficacia
T6	CHEM 131 143	donidalorsén
T7	PROC 149 173	tratamiento profiláctico
#1	AnnotatorNotes T7	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T8	DISO 178 200	angioedema hereditario
#2	AnnotatorNotes T8	C0019243; Angioedemas, Hereditary; Disease or Syndrome
T9	DISO 202 205	AEH
#3	AnnotatorNotes T9	C0019243; Angioedemas, Hereditary; Disease or Syndrome
T10	DISO 230 249	Enfermedad genética
#4	AnnotatorNotes T10	C0019247; Hereditary Diseases; Disease or Syndrome
T11	DISO 284 317	edemas subcutáneos y/o submucosos
T12	Duration 318 330	transitorios
T13	DISO 361 370	hinchazón
#5	AnnotatorNotes T13	C0038999; Swelling; Finding
T14	DISO 375 390	dolor abdominal
#6	AnnotatorNotes T14	C0000737; Abdominal Pain; Sign or Symptom
T15	DISO 417 439	angioedema hereditario
#7	AnnotatorNotes T15	C0019243; Angioedemas, Hereditary; Disease or Syndrome
T16	DISO 441 444	AEH
#8	AnnotatorNotes T16	C0019243; Angioedemas, Hereditary; Disease or Syndrome
T17	LIVB 479 492	participantes
T18	LIVB 519 533	representantes
#9	AnnotatorNotes T18	C0600419; Patient Agent; Group | C1708966; Medical Equipment Company Technician or Representative; Professional or Occupational Group
T19	LIVB 568 588	padre(s)/tutor legal
T20	PROC 627 651	consentimiento informado
#10	AnnotatorNotes T20	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T21	PROC 653 656	ICF
T22	LIVB 688 701	participantes
T23	CHEM 752 775	medicamento(s) agudo(s)
T24	CHEM 785 819	concentrado de C1-INH recombinante
T25	CHEM 822 840	derivado de plasma
T26	CHEM 846 893	antagonista del receptor de bradicinina (BK) 2)
T27	PROC 899 905	tratar
T28	DISO 910 931	ataques de angioedema
T29	LIVB 937 950	participantes
T30	PROC 1035 1088	estudio de índice aleatorizado controlado con placebo
T31	Date 1096 1108	la semana 25
T32	LIVB 1111 1124	participantes
T33	PROC 1188 1197	protocolo
#11	AnnotatorNotes T33	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T34	LIVB 1251 1264	Participantes
T35	Neg_cue 1273 1275	no
T36	Negated 1276 1303	previamente en donidalorsen
T37	LIVB 1322 1335	participantes
T38	Age 1348 1357	≥ 12 años
T39	PROC 1376 1400	consentimiento informado
#12	AnnotatorNotes T39	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T40	LIVB 1447 1460	participantes
T41	PROC 1476 1487	diagnóstico
#13	AnnotatorNotes T41	C0011900; Diagnosis; Diagnostic Procedure
T42	DISO 1503 1508	HAE-1
T43	DISO 1509 1514	HAE-2
T44	LIVB 1522 1535	participantes
T45	Dose 1551 1568	una dosis estable
T46	Duration 1569 1582	(≥ 12 semanas
T47	PROC 1587 1611	tratamiento profiláctico
#14	AnnotatorNotes T47	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T48	CHEM 1616 1627	lanadelumab
T49	CHEM 1630 1642	berotralstat
T50	CHEM 1645 1675	inhibidor de la esterasa SC C1
T51	CHEM 1844 1854	medicación
#15	AnnotatorNotes T51	C0013227; Pharmaceutical Preparations; Pharmacologic Substance
T52	LIVB 1855 1868	Participantes
T53	PROC 1880 1903	Diagnóstico concurrente
T54	DISO 1930 1940	angioedema
#16	AnnotatorNotes T54	C0002994; Angioedema; Pathologic Function
T55	DISO 1965 1996	angioedema idiopático adquirido
T56	DISO 1999 2002	AEH
#17	AnnotatorNotes T56	C0019243; Angioedemas, Hereditary; Disease or Syndrome
T57	DISO 2044 2056	AEH tipo III
T58	CHEM 2092 2102	andrógenos
#18	AnnotatorNotes T58	C0002844; Androgens; Hormone · Pharmacologic Substance
T59	PROC 2119 2129	profilaxis
#19	AnnotatorNotes T59	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T60	CHEM 2134 2151	ácido tranexámico
#20	AnnotatorNotes T60	C0040613; tranexamic acid; Organic Chemical · Pharmacologic Substance
T61	PROC 2157 2165	prevenir
#21	AnnotatorNotes T61	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T62	DISO 2166 2187	ataques de angioedema
T63	DISO 2198 2209	anormalidad
#22	AnnotatorNotes T63	C1704258; Abnormality; Finding
T64	PROC 2244 2279	valores de laboratorio de detección
T65	DISO 2283 2300	Neoplasia maligna
#23	AnnotatorNotes T65	C0006826; Malignant Neoplasms; Neoplastic Process | C1306459; Primary malignant neoplasm; Neoplastic Process
T66	Duration 2311 2321	los 5 años
T67	PROC 2339 2348	detección
#24	AnnotatorNotes T67	C1511790; Detection; Therapeutic or Preventive Procedure
T68	Neg_cue 2350 2364	a excepción de
T69	DISO 2369 2397	cánceres de piel no melanoma
#25	AnnotatorNotes T69	C0699893; Skin carcinoma; Neoplastic Process
T70	Negated 2369 2397	cánceres de piel no melanoma
T71	DISO 2402 2437	carcinoma in situ de cuello uterino
T72	Negated 2402 2437	carcinoma in situ de cuello uterino
T73	DISO 2442 2474	carcinoma ductal de mama in situ
T74	Negated 2442 2474	carcinoma ductal de mama in situ
T75	DISO 2480 2501	carcinoma de próstata
#26	AnnotatorNotes T75	C0600139; Prostate carcinoma; Neoplastic Process
T76	Negated 2480 2501	carcinoma de próstata
T77	PROC 2527 2534	tratado
T78	DISO 2549 2566	Hipersensibilidad
#27	AnnotatorNotes T78	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding | C0585186; Cutaneous hypersensitivity; Disease or Syndrome
T79	CHEM 2570 2586	principio activo
T80	CHEM 2588 2600	donidalorsen
T81	CHEM 2620 2631	excipientes
#28	AnnotatorNotes T81	C0015237; Pharmaceutical Excipient; Biomedical or Dental Material
T82	PROC 2635 2646	Tratamiento
#29	AnnotatorNotes T82	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T83	CHEM 2656 2680	fármaco en investigación
T84	Neg_cue 2682 2684	no
T85	CHEM 2685 2700	oligonucleótido
#30	AnnotatorNotes T85	C0028953; Oligonucleotides; Nucleic Acid, Nucleoside, or Nucleotide
T86	Negated 2685 2700	oligonucleótido
T87	CHEM 2704 2720	agente biológico
#31	AnnotatorNotes T87	C0005515; Biological Factors; Biologically Active Substance
T88	Duration 2736 2741	1 mes
T89	Duration 2763 2774	5 semividas
T90	CHEM 2779 2802	agente en investigación
T91	Date 2838 2846	reciente
T92	DISO 2849 2881	abuso actual de drogas o alcohol
T93	Date 2855 2861	actual
T94	CHEM 2921 2933	donidalorsen
T95	CHEM 2979 2991	medicamentos
#32	AnnotatorNotes T95	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0304228; Proprietary drug, NOS; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T96	CHEM 2993 3046	Inhibidores de la enzima convertidora de angiotensina
#33	AnnotatorNotes T96	C0003015; Angiotensin-Converting Enzyme Inhibitors; Pharmacologic Substance
T97	CHEM 3048 3051	ECA
#34	AnnotatorNotes T97	C0022709; Peptidyl-Dipeptidase A; Amino Acid, Peptide, or Protein · Enzyme · Immunologic Factor
T98	CHEM 3065 3076	medicamento
#35	AnnotatorNotes T98	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0304228; Proprietary drug, NOS; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T99	CHEM 3090 3099	estrógeno
#36	AnnotatorNotes T99	C0014939; estrogens; Hormone · Organic Chemical · Pharmacologic Substance
T100	PHYS 3104 3113	absorción
T101	CHEM 3124 3140	Oligonucleótidos
#37	AnnotatorNotes T101	C0028953; Oligonucleotides; Nucleic Acid, Nucleoside, or Nucleotide
T102	CHEM 3154 3197	ácido ribonucleico de interferencia pequeño
T103	CHEM 3199 3204	siRNA
T104	Duration 3217 3228	los 4 meses
T105	Dose 3270 3285	una dosis única
T106	Duration 3299 3311	los 12 meses
T107	Dose 3356 3371	dosis múltiples
T108	Neg_cue 3388 3390	no
T109	CHEM 3407 3414	vacunas
#38	AnnotatorNotes T109	C0042210; Vaccines; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T110	Negated 3407 3414	vacunas
T111	CHEM 2007 2013	C1-INH
T112	Route 1670 1672	SC
T113	Observation 333 344	recurrentes
T114	Quantifier_or_Qualifier 534 556	legalmente autorizados
T115	Observation 729 738	capacidad
T116	Quantifier_or_Qualifier 748 751	≥ 1
T117	Quantifier_or_Qualifier 767 772	agudo
T118	Observation 988 1014	Finalización satisfactoria
T119	Observation 1150 1167	salir del estudio
T120	Quantifier_or_Qualifier 1265 1271	nuevos
T121	Quantifier_or_Qualifier 1305 1314	SOLAMENTE
T122	Observation 1426 1438	asentimiento
T123	Observation 1750 1759	condición
T124	Quantifier_or_Qualifier 1760 1765	nueva
T125	Observation 1768 1781	empeoramiento
T126	Observation 1941 1951	recurrente
T127	Result_or_Value 2014 2020	normal
T128	Quantifier_or_Qualifier 2103 2116	concomitantes
T129	Quantifier_or_Qualifier 2210 2236	clínicamente significativa
T130	Quantifier_or_Qualifier 2505 2514	estadio 1
T131	Food 2874 2881	alcohol
T132	CONC 3378 3387	exclusión
T133	Patient 479 492	participantes
T134	Other 519 544	representantes legalmente
T135	Family_member 568 588	padre(s)/tutor legal
T136	Patient 688 701	participantes
T137	Patient 937 950	participantes
T138	Patient 1111 1124	participantes
T139	Patient 1251 1264	Participantes
T140	History_of 1291 1303	donidalorsen
T141	Patient 1322 1335	participantes
T142	Patient 1447 1460	participantes
T143	Patient 1522 1535	participantes
T144	History_of 1844 1854	medicación
T145	Patient 1855 1868	Participantes
T146	History_of 2527 2534	tratado
T147	History_of 2549 2566	Hipersensibilidad
T148	History_of 2704 2720	agente biológico
T149	History_of 2779 2785	agente
T150	History_of 2849 2881	abuso actual de drogas o alcohol
T151	History_of 2901 2908	estudio
T152	History_of 2921 2933	donidalorsen
